Biotech

All Articles

Lykos will inquire FDA to reconsider its own selection following rejection of MDMA therapy for post-traumatic stress disorder

.Complying with an inadequate revealing for Lykos Therapies' MDMA candidate for trauma at a recent F...

AN 2 fifty percents headcount, quits phase 3 trial after records disappoint

.AN2 Therapeutics is re-thinking its own company in action to poor midphase records, pledging to lay...

Merck spends $700M for bispecific, spying autoimmune position as well as opportunity to test Amgen in cancer cells

.Merck &amp Co. is actually spending $700 thousand ahead of time to challenge Amgen in a blood strea...

Gilead pays J&ampJ $320M to go out licensing package for seladelpar

.With Gilead Sciences about to an FDA decision for its own liver illness drug seladelpar, the busine...

' All palms on deck' at Lilly as peers target excessive weight market

.Chief executive officer David Ricks may observe the providers establishing tents at basecamp respon...

Entero laying off staff, abandoning workplace and stopping briefly R&ampD

.Bed mattress Liquidators has actually turned Entero Rehabs white colored as a sheet. The collector ...

Exelixis goes down ADC after determining it is actually no suit for Tivdak

.Exelixis is actually giving up on its tissue aspect (TF)- targeting antibody-drug conjugate after w...

Relay loses interest in SHP2 prevention after Genentech leaves

.3 full weeks after Roche's Genentech unit left an SHP2 prevention treaty, Relay Rehab has confirmed...

Stoke's Dravet disorder med launched of partial clinical hold

.Stoke Therapeutics' Dravet syndrome drug has been without a partial grip, clearing the means for th...

Fierce Biotech's Gabrielle Masson shows Strong 15 at NYSE

.Strong Biotech Partner Publisher Gabrielle Masson presented the 2024 lesson of Ferocious 15 champio...